Mayne Pharma has completed its $652 million transaction with Teva and Allergan, gaining 37 approved and five filed generic pharmaceutical products. This transaction is among the largest generic pharmaceutical divestitures and follows Teva’s $40.5 billion acquisition of Allergan’s generic drug business. Mayne Pharma acquired more products than the other 11 buyers.   The acquired portfolio aligns with Mayne Pharma’s focus in complex drug delivery formulations and technologies and includes trans...